Skip to content

New Trial Medication for Pulmonary Arterial Hypertension

Search Clinical Trials

Trial Objectives

The new investigational drug Ralinepag is designed to help the body receive prostacyclin known to widened blood vessels and relax artery walls, and potentially improve blood flow in adults with Pulmonary Arterial Hypertension (PAH). The ADVANCE OUTCOMES study is evaluating the effects of adding Ralinepag, to patients’ current PAH therapies. Once screened, participants will have 16 weeks to find their optimal dose before continuing to treatment.

Participants will have the option to continue in an extension study of Ralinepag (ADVANCE-extension) if they are eligible. The extension study will look at the effect of Ralinepag over a longer period of time.

Who Can Participate

Adults between 18 and 75 who have been diagnosed with Pulmonary Arterial Hypertension.

Age: 18-75 Gender Any

Estimated Time Commitment

Up to 42 months

Time Commitment Details

The first four weeks will be spent screening participants. This will be followed by 16 weeks to find the optimal dosage for participants, after which treatment will start and patients will check in every 12 weeks until the end of the study, which is individual to each participant. After treatment there will be a final follow up after 30 days. There will be both clinic visits and telephone calls throughout the trial.

Payment & Reimbursement

Payment Provided

Travel Reimbursement Available

Trial Contact

For more information, contact:

Jennifer Underwood

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

United Therapeutics

Principal Investigators

Marjorie Patricia George

Marjorie Patricia George, MD


  • Andrew M. Freeman

    Andrew M. Freeman, MD, FACC, FACP

  • Darlene Kim

    Darlene Kim, MD, FACC

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required